Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

26.1%

6 terminated/withdrawn out of 23 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

35%

8 trials in Phase 3/4

Results Transparency

20%

3 of 15 completed trials have results

Key Signals

3 with results6 terminated

Enrollment Performance

Analytics

Phase 2

10(47.6%)

Phase 3

6(28.6%)

Phase 1

3(14.3%)

Phase 4

2(9.5%)

21Total

Phase 2(10)

Phase 3(6)

Phase 1(3)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials

NCT02176707Unknown

Modelling of Quality Life, Clinical and Physiological Measures in Idiopathic Pulmonary Fibrosis

Role: collaborator

NCT00211692Phase 3Completed

Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial

Role: collaborator

NCT00501644Phase 2Completed

Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer

Role: collaborator

NCT00786643Phase 2Completed

Study of Gamma Interfereon in Metastatic Colorectal Carcinoma

Role: collaborator

NCT00207402Phase 4Completed

Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin

Role: collaborator

NCT00753467Phase 2Unknown

A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B

Role: collaborator

NCT00084279Phase 2Completed

CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)

Role: lead

NCT00075998Phase 3Terminated

The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)

Role: lead

NCT00012467Phase 2Completed

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

Role: lead

NCT00266318Phase 4Completed

Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy

Role: collaborator

NCT00076635Phase 3Terminated

An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

Role: lead

NCT00047658Phase 2Completed

A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Role: lead

NCT00052039Phase 3Terminated

A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone

Role: lead

NCT00052052Phase 2Completed

An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Role: lead

NCT00047645Phase 3Completed

A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Role: lead

NCT00057447Phase 1Terminated

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Role: lead

NCT00043342Phase 1Completed

Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis

Role: lead

NCT00043355Phase 2Terminated

Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection

Role: lead

NCT00043316Phase 1Completed

Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis

Role: lead

NCT00043329Completed

Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis

Role: lead